Key clinical point: Improved renal cell carcinoma survival appears to be attributable to improvements in therapy rather than increased diagnosis of early-stage disease.
Major finding: 5-year survival increased from 9.8% in 2004 to 13.2% in 2010 for patients with distant metastatic disease.
Study details: Retrospective analysis of data from the National Cancer Database on 262,597 patients diagnosed with RCC from 2004 through 2015.
Disclosures: No study funding source was reported. Dr. Patel and coauthors reported having no conflicts of interest to disclose.
Patel HD et al. Eur Urol Oncol. 2018 Sep 25. doi: 10.1016/j.euo.2018.08.023
This Week's Must Reads
Must Reads in Renal Cell Carcinoma
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4
Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010